Clover Health Investments annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Clover Health Investments Stock-Based Compensation Growth & History (CLOV)
Clover Health Investments's stock-based compensation was $103.7M for fiscal 2025.
View full Clover Health Investments company overviewClover Health Investments annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $103.7M | −$10.7M | −9.34% |
| 2024 | 2024-12-31 | $114.3M | −$26.6M | −18.87% |
| 2023 | 2023-12-31 | $140.9M | −$23.4M | −14.23% |
| 2022 | 2022-12-31 | $164.3M | $582,000 | +0.36% |
| 2021 | 2021-12-31 | $163.7M | $156.6M | +2213.13% |
| 2020 | 2020-12-31 | $7.1M | $3.8M | +114.42% |
| 2019 | 2019-12-31 | $3.3M | — | — |
Clover Health Investments quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.1M | −$17.1M | −65.32% |
| Q1 2026 | 2026-03-31 | $12.3M | −$14.2M | −53.58% |
| Q4 2025 | 2025-12-31 | $24.9M | −$4.7M | −15.94% |
| Q3 2025 | 2025-09-30 | $26.1M | −$1.9M | −6.72% |
| Q2 2025 | 2025-06-30 | $26.2M | −$1.7M | −6.11% |
| Q1 2025 | 2025-03-31 | $26.4M | −$2.4M | −8.20% |
| Q4 2024 | 2024-12-31 | $29.6M | −$3.5M | −10.54% |
| Q3 2024 | 2024-09-30 | $28.0M | −$5.1M | −15.37% |
| Q2 2024 | 2024-06-30 | $27.9M | −$8.2M | −22.73% |
| Q1 2024 | 2024-03-31 | $28.8M | −$9.8M | −25.43% |
| Q4 2023 | 2023-12-31 | $33.1M | −$6.0M | −15.24% |
| Q3 2023 | 2023-09-30 | $33.1M | −$9.6M | −22.45% |
| Q2 2023 | 2023-06-30 | $36.1M | −$5.8M | −13.88% |
| Q1 2023 | 2023-03-31 | $38.6M | −$2.0M | −4.98% |
| Q4 2022 | 2022-12-31 | $39.1M | $7.9M | +25.38% |
| Q3 2022 | 2022-09-30 | $42.6M | −$4.2M | −8.89% |
| Q2 2022 | 2022-06-30 | $41.9M | −$1.1M | −2.55% |
| Q1 2022 | 2022-03-31 | $40.6M | −$2.1M | −4.85% |
| Q4 2021 | 2021-12-31 | $31.2M | $29.1M | +1364.58% |
| Q3 2021 | 2021-09-30 | $46.8M | $45.3M | +3018.12% |
| Q2 2021 | 2021-06-30 | $43.0M | $41.6M | +2824.95% |
| Q1 2021 | 2021-03-31 | $42.7M | $40.7M | +2060.50% |
| Q4 2020 | 2020-12-31 | $2.1M | — | — |
| Q3 2020 | 2020-09-30 | $1.5M | — | — |
| Q2 2020 | 2020-06-30 | $1.5M | — | — |
| Q1 2020 | 2020-03-31 | $2.0M | — | — |
Clover Health Investments stock-based compensation trends
Over the last five fiscal years, Clover Health Investments's stock-based compensation increased from $7.1M to $103.7M, a change of $96.6M. The latest reported quarter, Q2 2026, shows $9.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Clover Health Investments source filings ↗